<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518826</url>
  </required_header>
  <id_info>
    <org_study_id>FFRCAG</org_study_id>
    <nct_id>NCT04518826</nct_id>
  </id_info>
  <brief_title>A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES</brief_title>
  <official_title>A Comparison Between Fractional Flow Reserve Guided and Coronary Angiography Guided Treatment Using Drug Eluting Balloon in In-stent Restenosis of Drug Eluting Stent: a Single-center, Prospective, Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single center, randomized controlled clinical study aimed to compare&#xD;
      the clinical and angiographic follow-up results of patients with in-stent restenosis(ISR)&#xD;
      after coronary drug eluting stent(DES) implantation treated by fractional flow reserve&#xD;
      -guided and angiography guided drug eluting balloon(DEB) intervention. This study intends to&#xD;
      confirm the clinical benefits of optimizing DEB intervention of DES-ISR by FFR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      420 patients with DES-ISR will be recruited in this study. After angiography, patients with&#xD;
      DES-ISR to be treated with DEB will be randomly assigned to FFR-guided and angiography-guided&#xD;
      groups. In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR&#xD;
      lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR &lt;0.9,&#xD;
      the operator will dilate the DES-ISR lesion again before another FFR is measured. If&#xD;
      FFR&gt;=0.9, DEB will be used and final FFR will be measured at the end of the procedure. In&#xD;
      angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant&#xD;
      balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>target vessel failure</measure>
    <time_frame>12 month</time_frame>
    <description>cardiac death, target vessel myocardial infarction, target vessel failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>angiographic outcomes</measure>
    <time_frame>12 month</time_frame>
    <description>diameter stenosis, binary stenosis and late lumen loss measured by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel failure</measure>
    <time_frame>36 month</time_frame>
    <description>cardiac death, target vessel myocardial infarction, target vessel failure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>In Stent Restenosis</condition>
  <condition>Drug Eluting Stent</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>FFR</arm_group_label>
    <description>In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR &lt;0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR&gt;=0.9, DEB will be used and final FFR will be measured at the end of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAG</arm_group_label>
    <description>In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fractional flow reserve</intervention_name>
    <description>FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.</description>
    <arm_group_label>FFR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with coronary artery disease and DES implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In-stent restenosis(ISR) occurred more than 6 months after drug eluting stent (DES)&#xD;
        implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ISR in bare metal stents and biodegradable stents&#xD;
&#xD;
          2. Complicated with immune diseases&#xD;
&#xD;
          3. ISR in left main DES&#xD;
&#xD;
          4. Suffer from renal failure requiring dialysis treatment or is undergoing dialysis&#xD;
             treatment&#xD;
&#xD;
          5. Severe cardiac insufficiency (LVEF &lt;30%)&#xD;
&#xD;
          6. Subjects with ST segment elevation myocardial infarction within 7 days of onset of&#xD;
             chest pain&#xD;
&#xD;
          7. Pregnant or lactating women&#xD;
&#xD;
          8. Combined with other diseases, life expectancy &lt;1 year&#xD;
&#xD;
          9. Follow - up visits required by the protocol cannot be followed, or the investigators&#xD;
             believe that the participation of subjects in the trial will increase the risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Qin, MD</last_name>
    <phone>021-64041990</phone>
    <phone_ext>5112</phone_ext>
    <email>qin.qing@zs-hospital.sh.cn</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fractional flow reserve</keyword>
  <keyword>in stent restenosis</keyword>
  <keyword>drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

